Peter L Molloy, Executive Chairman & Founder
BSc, MBA, FAICD
Peter Molloy trained as a microbiologist and biochemist and subsequently built a successful career in the international pharmaceutical industry. At Pharmacia (Pfizer) he was Managing Director of Australia/NZ operations and later Vice President for Strategic Marketing, responsible for the marketing of hundreds of pharmaceuticals across 22 countries. During his pharmaceutical career, he has directly launched 23 new pharmaceutical products and executed 40 international licensing or distribution deals. Subsequently, as CEO of four biotech companies, he has led numerous R&D programs, moved several drugs from research into human clinical trials, and executed four valuable international pharmaceutical partnerships including two $100m+ licensing deals. In 2002-2005 he was CEO of one of the world's leading antiviral research companies, Biota Holdings Limited, where during his term the company’s market value increased from $30m to around $300m. He has extensive knowledge and expertise in the development and marketing of oral and topical antimicrobial agents, and at Biota managed R&D programs focused on new drug treatments for respiratory viral diseases.
Dr Stephen Goodall, COO & Co-founder
BAppSc, MAppSc, MBA, PhD
Stephen Goodall has a successful track record in intellectual property, pharmaceutical development, manufacturing, regulatory strategy and clinical development. He was instrumental in developing the intellectual property that underpins the Firebrick patent. Previously, he was COO of Viralytics and founder and COO of cBio (now Invion) both of which are ASX-listed companies. Previously, he was the Director of Pharmaceutical Development at Vapotronics, where he managed all aspects of inhaled drug development and formulation and before that, Director of Development at AGEN Biomedical for 11 years. He has extensive experience in the preclinical, IND, regulatory and human clinical phases of drug development. He also has an impressive background in process development, production scale-up and GMP manufacturing for pharmaceuticals.
Dr Phillip Altman, Non-executive Director
BPharm, MSc, BSc, PhD
Dr Altman is a highly respected expert
consultant in regulatory affairs and clinical development and has more than 30 years’ experience in clinical research and regulatory affairs. He has been involved in more than a hundred
clinical trials and has been personally responsible for the market approval of numerous new drugs and dosage forms involving both prescription and OTC products. Dr Altman has consulted to most of the
leading Australian and international pharmaceutical and biotech companies and is experienced in setting R&D strategy, developing detailed research plans, the design and supervision of clinical
research projects and the generation of documentation to meet local and international registration requirements. Dr Altman established the first full service Clinical Research Organisation (CRO) in
Australia and founded the Association of Clinical and Regulatory Scientists Australia (ARCS) and was awarded Life Membership.